NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.
Additionally, Dr. Zhang was invited as a speaker on the panel “Maximize Your Asset’s Potential Value for Deal Making” at the Fierce BD&L Summit for Life Sciences, to be held March 15-16 in San Francisco, CA, where he will present “NT-I7 Strategic Positioning via Clinical Collaborations with Global I-O Leaders” as a case study. Subsequently, he will join a panel discussion titled “Getting your House in Order: Strategies for Sellers to Best Prepare for a Diligence Review”.
The details of the company’s presentations are as follows:
BIO CEO and Investor Conference
Date: Tuesday, February 15th, 2022
Time: 11:15am ET
Website: BIO CEO & Investor Conference | BIO
Fierce BD&L Summit for Life Sciences
Date: Wednesday, March 16th, 2022
Time: 9:30am PT (case study), 9:45am PT (panel discussion)
Website: Agenda | BDL Summit